FluoroPharma is developing breakthrough molecular imaging agents for use with positron emission tomography (PET) designed to fulfill critical unmet medical needs. These new agents give clinicians crucial tools for the detection and assessment of pathology before clinical manifestation of diseases. … Continue reading →

FluoroPharma, a developer of imaging drugs that underpin important diagnostic capabilities of positron emission tomography (PET), targets a fast-growing market. This market is currently over $7 billion in size and is expected to top $15 billion in 2015. One of … Continue reading →

FluoroPharma Medical is a New Jersey based developer of advanced imaging pharmaceuticals for use with positron emission tomography (PET). The company provides unique radiopharmaceutical imaging agents, unavailable from other sources, that allow PET technology to detect critical bioprocesses in the … Continue reading →

One of the buzzword terms in modern medicine today is “personalized medicine”. Instead of simply matching a drug or treatment to an over-arching disease based on a one-size-fits-all philosophy, as has been done in the past, the move now is … Continue reading →

FluoroPharma Medical, Inc. is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing four different … Continue reading →

Earlier this week, LifeTech Capital issued an update on its FluoroPharma Medical coverage. The latest report reiterates the stock as a “Strong Speculative Buy” and sets a $2.50 price target. The entire 23-page report can be viewed at the following … Continue reading →

In 1950, the FBI formally announced their Ten Most Wanted list to the world, in an attempt to promote the identification and capture of the most notorious fugitives. If there were a ten most wanted health list, coronary artery disease … Continue reading →

For developing businesses, one of the keys to potential growth is to present products that have unique benefits not found elsewhere, providing a decided advantage in the marketplace. In the rapidly expanding field of molecular imaging, FluoroPharma Medical differentiates itself … Continue reading →